Arax Advisory Partners’s Cardiol Therapeutics CRDL Stock Holding History

Arax Advisory Partners’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83K	Buy	+1,724	New	+$2.18K	﹤0.01%	4833

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's CRDL Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Cardiol Therapeutics (CRDL) in Q2 2026: 1,724 shares worth $1.83K. The stake represents ﹤0.01% of the portfolio and ranks #4833 among its holdings.

52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Arax Advisory Partners held 1,724 shares of Cardiol Therapeutics worth $1.83K as of Q2 2026.
Cardiol Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Cardiol Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4833 holding.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.